Insulet Corporation (NASDAQ:PODD) Stock Has Consensus Target Price of $195.40

Key Points

• Analysts have a consensus “Hold” rating on Insulet, with 13 buys, 11 holds, and 2 sells among 26 firms. The average 12-month price target is $195.40.
• Insulet reported quarterly EPS of $1.66, exceeding the $1.47 consensus estimate, while revenue rose 23.5% year over year to $801.7 million.
• The stock opened at $132.84, well below its 12-month high of $354.88; several analysts recently reduced their price targets, including Wells Fargo, Truist Financial, and Stifel Nicolaus.

Insulet Corporation (NASDAQ:PODD - Get Free Report) has earned an average recommendation of "Hold" from the twenty-six ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $195.40.

A number of analysts have weighed in on the stock. Robert W. Baird set a $175.00 price objective on shares of Insulet in a report on Thursday, August 6th. Truist Financial restated a "hold" rating and issued a $153.00 price objective (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Stifel Nicolaus dropped their price objective on Insulet from $225.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Wells Fargo & Company cut Insulet from an "overweight" rating to an "equal weight" rating and cut their target price for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. Finally, Evercore set a $180.00 target price on Insulet in a research report on Monday, July 6th.

Insulet Stock Performance

NASDAQ:PODD opened at $132.84 on Wednesday. Insulet has a 12 month low of $126.40 and a 12 month high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The firm has a market capitalization of $9.21 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.05 and a beta of 1.08. The business's fifty day moving average price is $146.67 and its 200 day moving average price is $164.50.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million during the quarter, compared to the consensus estimate of $787.39 million. During the same period in the previous year, the business earned $1.17 EPS. Insulet's revenue for the quarter was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, sell-side analysts anticipate that Insulet will post 6.51 earnings per share for the current fiscal year.

Institutional Trading of Insulet

Several institutional investors and hedge funds have recently bought and sold shares of the business. MV Capital Management Inc. acquired a new position in Insulet in the fourth quarter valued at $29,000. Fideuram Asset Management Ireland dac acquired a new stake in shares of Insulet during the fourth quarter worth about $41,000. Continuum Advisory LLC acquired a new stake in shares of Insulet during the second quarter worth about $46,000. Sound Income Strategies LLC grew its holdings in shares of Insulet by 4,620.0% during the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier's stock worth $49,000 after buying an additional 231 shares during the last quarter. Finally, State of Wyoming grew its holdings in shares of Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock worth $60,000 after buying an additional 73 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet's product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.